Though two serious side effects muddied the results, CEO Curran Simpson expressed optimism about a clearance and claimed FDA ...

Marty Makary's resignation leaves the agency with temporary directors in three top positions, and a number of newly ...

A pair of trial results published in medical journals suggest switching from high-dose injectables to lower doses or pills could help people with obesity keep their weight down over the long term.

Journavx revived an area of development long considered a graveyard. Can any other pain drugs keep investor excitement going?

Assertio’s latest offer represents a roughly 31% premium over an initial acquisition proposal. Elsewhere, Kyverna is readying a first-of-its-kind approval application and AC Immune is swapping CEOs.

Cell and gene therapies aren’t limited by ideas—they’re limited by where they’re built. See how “ready-now” locations change ...

The wide-ranging pact involves as many as 13 drugs and marks the latest example of the growing relationship between Chinese ...

Makary’s exit ends a turbulent run marred by leadership upheaval, mass layoffs, political pressure and public spats with ...

The acquisition hands the Italian pharma a group of medicines approved to treat various CNS disorders and gives it wider ...

The marketing deal is the latest in a series of recent pacts between GSK and China-based drug companies, and could speed ...

After withdrawing its initial filing last year, the immune drugmaker rebounded and added to a recent run of sizable new ...

Inhibrx, the subject of recent buyout rumors, showed its drug might enhance the effects of Keytruda. Elsewhere, Capricor sued its cell therapy partner and Argenx got a revenue boost.